<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04135495</url>
  </required_header>
  <id_info>
    <org_study_id>EL-012</org_study_id>
    <nct_id>NCT04135495</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele</brief_title>
  <official_title>A Phase 2 Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dose Levels of Subcutaneously Administered ELX-02 in Patients With Cystic Fibrosis With at Least One G542X Allele</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eloxx Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eloxx Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 open-label, dose-escalation study to evaluate the safety, tolerability, PK,
      and PD of multiple dose levels of SC administered ELX-02 in patients with CF with at least
      one G542X allele.

      In total, up to eight patients will be enrolled in the trial; up to 4 patients will be
      homozygotes to G542X, and the remaining patients will be compound heterozygotes with G542X
      and with any Class 1 or Class 2 mutation, excluding F508del.

      Each patient will receive 4 escalating doses as follows:

        -  0.3 mg/kg per day SC

        -  0.75 mg/kg per day SC

        -  1.5 mg/kg per day SC

        -  An individualized dose, as high as 3.0 mg/kg per day SC, based on the patients observed
           safety and tolerability, PK at previous doses and the results of laboratory tests.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 25, 2019</start_date>
  <completion_date type="Anticipated">June 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AEs associated with different dose levels of ELX-02</measure>
    <time_frame>From the time of first dosing through the follow-up visit, an average of approximately 9 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration curve from time zero to 24 hours (AUC0-24h)</measure>
    <time_frame>Day 1 of treatment periods 1, 2, 3, and 4</time_frame>
    <description>Full PK profile 12 blood samples over 24 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Day 1 of treatment periods 1, 2, 3, and 4</time_frame>
    <description>Full PK profile 12 blood samples over 24 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Observed plasma concentration at 1 hour post dose (C1h)</measure>
    <time_frame>Days 1, 2, and 7 of treatment periods 1-3; Days 1, 2, 7, and 14 of treatment period 4</time_frame>
    <description>Sparse sampling, blood sampling only, pre-dose and 1 hour post dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in forced expiratory volume (FEV1)</measure>
    <time_frame>Screening, Days 1 &amp; 7 of treatment periods 1-3, and Days 1, 7, and 14 of treatment period 4, and 4 weeks following last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in forced vital capacity (FVC)</measure>
    <time_frame>Screening, Days 1 &amp; 7 of treatment periods 1-3, and Days 1, 7, and 14 of treatment period 4, and 4 weeks following last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in forced expiratory flow at 25-75% (FEF25-75)</measure>
    <time_frame>Screening, Days 1 &amp; 7 of treatment periods 1-3, and Days 1, 7, and 14 of treatment period 4, and 4 weeks following last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in baseline sweat chloride concentration</measure>
    <time_frame>Screening, Day 7 of treatment periods 1-3, and Day 1, 7 and 14 of treatment period 4, and 4 weeks following last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>ELX-02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eukaryotic ribosomal selective glycoside (ERSG)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ELX-02</intervention_name>
    <description>ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaroyotic ribosomal selective glycoside (ERSG)</description>
    <arm_group_label>ELX-02</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females age 18 years and above

          2. A confirmed diagnosis of nmCF with a documented G542X mutation, homozygote, or
             compound heterozygote with one of the specified mutations. For heterozygotes, one
             mutation has to be G542X, and the second mutation has to be any Class 1 or Class 2
             mutation excluding F508del. Patients with one G542X allele and a second allele that is
             not a Class 1 or Class 2 mutation may be potentially allowed but only after discussion
             on a case by case basis with and written approval from the Sponsor.

          3. Documented SCC ≥60 mEq

          4. FEV1 ≥40% predicted normal for age, gender and height at Screening (Knudson Equation)

          5. Body mass index (BMI) of 19.0 to 30.0 kg/m2 (inclusive). Patients with a lower BMI may
             be entered into the study at the discretion of the investigator following consultation
             with the Sponsor.

        Exclusion Criteria:

          1. Participation in clinical study including administration of any investigational drug
             or device in the last 30 days or 5 half-lives (whichever is longer) prior to
             investigational product dosing in the current study

          2. History of any organ transplantation

          3. Major surgery within 180 days (6 months) of Screening

          4. Patients without documented prior aminoglycoside exposure who have a mitochondrial
             mutation that has been shown to increase sensitivity to aminoglycosides

          5. Known allergy to any aminoglycoside

          6. Patients with any abnormality at ENT screening, that indicates the presence of a
             vestibular toxicity associated with prior exposure to aminoglycosides.

          7. Dizziness Handicap Inventory (DHI)-H score at screening must be &gt;16.

          8. Patients receiving CFTR modulators within 2 months of study treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eloxx Pharmaceuticals</last_name>
    <phone>7815775300</phone>
    <email>CTI@eloxxpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Long Beach Memorial</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jimmy Johannes, MD</last_name>
      <phone>614-722-4756</phone>
      <email>Terri.Johnson@nationwidechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Candice Evans</last_name>
      <phone>562-933-5607</phone>
      <email>cevans@memorialcare.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jimmy Johannes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford School of Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Milla, MD</last_name>
      <phone>650-493-5193</phone>
      <email>cmilla@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Monica Elazar</last_name>
      <phone>650 - 493-5193</phone>
      <email>monica8@stanford.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Carlos Milla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02451</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uluer Ahmet, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen McCoy, MD</last_name>
      <phone>614-722-4766</phone>
      <email>Karen.McCoy@nationwidechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Terri Johnson</last_name>
      <phone>614-722-4756</phone>
      <email>Terri.Johnson@nationwidechildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Karen McCoy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tara Barto, MD</last_name>
      <phone>832-824-1508</phone>
      <email>tara.barto@bcm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nicoline Schaap</last_name>
      <phone>832-822-4252</phone>
      <email>nxschaap@texaschildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Tara Barto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 16, 2019</study_first_submitted>
  <study_first_submitted_qc>October 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2019</study_first_posted>
  <last_update_submitted>March 5, 2020</last_update_submitted>
  <last_update_submitted_qc>March 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cystic fibrosis</keyword>
  <keyword>ELX-02</keyword>
  <keyword>G542X allele</keyword>
  <keyword>eukaryotic ribosomal selective glycoside</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

